Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.71 |
| ▸ | RAF1 | P04049 | 5/20 | 0.56 |
| ▸ | BRAF | P15056 | 4/20 | 0.56 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14350415 | 0.89 | MAPK14 (0.69) | MAPK14RAF1BRAFHSPB1LYN | |
| SCHEMBL4704265 | 0.84 | MAPK14 (0.70) | MAPK14RAF1HSPB1LYNMAPK13 | |
| SCHEMBL4821477 | 0.83 | MAPK14 (1.00) | MAPK14RAF1HSPB1LYNMAPK13 | |
| SCHEMBL13198154 | 0.80 | MAPK14 (0.61) | MAPK14RAF1BRAFMAPK11 | |
| SCHEMBL31524034 | 0.79 | MAPK14 (0.56) | MAPK14RAF1BRAFMAPK11 | |
| SCHEMBL4700704 | 0.79 | MAPK14 (0.64) | MAPK14RAF1HSPB1LYNMAPK13 | |
| SCHEMBL4700699 | 0.79 | MAPK14 (0.74) | MAPK14RAF1BRAFHSPB1LYN | |
| SCHEMBL2348556 | 0.79 | MAPK14 (0.67) | MAPK14BRAFHSPB1MAPK13MAPK12 | |
| SCHEMBL2914638 | 0.77 | MITF (0.64) | MAPK14HSPB1ABL1 | |
| SCHEMBL2914486 | 0.77 | KMT2A (0.57) | MAPK14HSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7626055-B2 | Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| US-7309800-B2 | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-7271289-B2 | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070105850-A1 | Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-05-10 | — | — | US | disclosed |
| US-7183297-B2 | Biphenyl-derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK3 | MAPK14 6/4885RAF1 67/4885BRAF 47/4885 |
| US-20070105850-A1 | Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors | MAPK1, MAPKAPK2, MAP3K8 | MAPK14 10/4885RAF1 58/4885BRAF 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.